Cargando…

Spontaneous virologic suppression in HIV controllers is independent of delayed-type hypersensitivity test responsiveness

BACKGROUND: Delayed-type hypersensitivity (DTH) testing, an in vivo assessment of cell-mediated immunity, is a predictor of HIV disease progression beyond CD4 cell count. We investigated whether preserved DTH responsiveness was characteristic of HIV controllers compared to non-controllers and indivi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okulicz, Jason F, Grandits, Greg A, Dolan, Matthew J, Marconi, Vincent C, Wortmann, Glenn, Landrum, Michael L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352025/ https://www.ncbi.nlm.nih.gov/pubmed/22472163 http://dx.doi.org/10.1186/1742-6405-9-10

Ejemplares similares

Cumulative Viral Load and Virologic Decay Patterns after Antiretroviral Therapy in HIV-Infected Subjects Influence CD4 Recovery and AIDS
por: Marconi, Vincent C., et al.
Publicado: (2011)

Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study
por: Marconi, Vincent C, et al.
Publicado: (2010)

Delayed-type hypersensitivity (DTH) test anergy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapy
por: Minidis, Natascha M, et al.
Publicado: (2014)

Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study
por: Okulicz, Jason F, et al.
Publicado: (2011)

CD4 rate of increase is preferred to CD4 threshold for predicting outcomes among virologically suppressed HIV-infected adults on antiretroviral therapy
por: Aldrete, Sol, et al.
Publicado: (2020)

The Impact of Continuous Virologic Suppression on the Development of Non-AIDS Diagnoses
por: Joya, Christie, et al.
Publicado: (2017)

Studies on delayed hypersensitivity in mice. III. Evidence for suppressive regulatory T1-cell population in delayed hypersensitivity
Publicado: (1977)

IMMUNOCHEMICAL STUDY OF ANTIGENIC SPECIFICITY IN DELAYED HYPERSENSITIVITY : II. DELAYED HYPERSENSITIVITY TO POLYTYROSINE-AZOBENZENEARSONATE AND ITS SUPPRESSION BY HAPTENS
por: Leskowitz, Sidney
Publicado: (1963)

Desensitization of delayed-type hypersensitivity in mice: suppressive environment
por: Katsura, Takashi, et al.
Publicado: (1993)

SUPPRESSION OF DELAYED HYPERSENSITIVITY IN VITRO BY INHIBITION OF PROTEIN SYNTHESIS
por: David, John R.
Publicado: (1965)

SELECTIVE SUPPRESSION OF DELAYED HYPERSENSITIVITY BY THE INDUCTION OF IMMUNOLOGIC TOLERANCE
por: Borel, Yves, et al.
Publicado: (1966)

Hospitalizations among HIV controllers and persons with medically controlled HIV in the U.S. Military HIV Natural History Study
por: Crowell, Trevor A, et al.
Publicado: (2016)

Analysis of HIV quasispecies and virological outcome of an HIV D+/R+ kidney–liver transplantation
por: Rozera, Gabriella, et al.
Publicado: (2022)

Alcohol use, suicidality and virologic non‐suppression among young adults with perinatally acquired HIV in Thailand: a cross‐sectional study
por: Aurpibul, Linda, et al.
Publicado: (2023)

Delayed Hypersensitivity
por: Waksman, Byron H.
Publicado: (1968)

IN VITRO STUDIES OF THE SUPPRESSION OF DELAYED HYPERSENSITIVITY BY THE INDUCTION OF PARTIAL TOLERANCE
por: Borel, Yves, et al.
Publicado: (1970)

MECHANISMS IN THE SUPPRESSION OF DELAYED HYPERSENSITIVITY IN THE GUINEA PIG BY 6-MERCAPTOPURINE
por: Phillips, S. Michael, et al.
Publicado: (1973)

In vivo suppression of delayed hypersensitivity: prolongation of desensitization in guinea pigs
Publicado: (1975)

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy
por: Gianotti, Nicola, et al.
Publicado: (2015)

Association between depression and HIV treatment outcomes in a US military population with HIV infection
por: Carney, Brandon, et al.
Publicado: (2021)

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
por: Wijting, IEA, et al.
Publicado: (2018)

Immunologic and Virologic Outcomes of Obese and Nonobese Incarcerated Adults on Antiretroviral Therapy for HIV Infection
por: Bunnell, Kristen L., et al.
Publicado: (2018)

Fexofenadine Suppresses Delayed-Type Hypersensitivity in the Murine Model of Palladium Allergy
por: Matsubara, Ryota, et al.
Publicado: (2017)

REGULATION OF DELAYED HYPERSENSITIVITY : FAILURE TO TRANSFER DELAYED HYPERSENSITIVITY TO DESENSITIZED GUINEA PIGS
por: Dwyer, J. M., et al.
Publicado: (1973)

Impact of the highly active antiretroviral therapy era on the epidemiology of primary HIV-associated thrombocytopenia
por: O’Bryan, Thomas A., et al.
Publicado: (2015)

Virological outcome among HIV-1 infected patients on first-line antiretroviral treatment in semi-rural HIV clinics in Togo
por: Konou, Abla A., et al.
Publicado: (2015)

DELAYED HYPERSENSITIVITY : V. THE EFFECT OF X-IRRADIATION ON THE DEVELOPMENT OF DELAYED HYPERSENSITIVITY AND ANTIBODY FORMATION
por: Uhr, Jonathan W., et al.
Publicado: (1960)

STUDIES OF DELAYED HYPERSENSITIVITY IN VITRO : II. DELAYED HYPERSENSITIVITY IN EXPERIMENTAL MUMPS VIRUS INFECTIONS
por: Glasgow, Lowell A., et al.
Publicado: (1957)

Association between quantitative varicella-zoster virus antibody levels and zoster reactivation in HIV-infected persons
por: Pomerantz, Heather S., et al.
Publicado: (2018)

Ly and Ia antigen phenotypes of T cells involved in delayed-type hypersensitivity and in suppression
Publicado: (1976)

Antibodies Enhance the Suppressive Activity of Extracellular Vesicles in Mouse Delayed-Type Hypersensitivity
por: Nazimek, Katarzyna, et al.
Publicado: (2021)

OCCURRENCE OF DELAYED HYPERSENSITIVITY DURING THE DEVELOPMENT OF ARTHUS TYPE HYPERSENSITIVITY
por: Salvin, S. B.
Publicado: (1958)

Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months’ antiretroviral therapy experience in Cameroon
por: Aghokeng, Avelin F, et al.
Publicado: (2013)

Retrospective Review of Virologic and Immunologic Response in Treatment-Experienced Patients on Third-Line HIV Therapy in Lusaka, Zambia
por: Zulu, Paul Msanzya, et al.
Publicado: (2021)

Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection
por: Lodi, Sara, et al.
Publicado: (2022)

571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed
por: Ganesan, Anuradha, et al.
Publicado: (2018)

Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
por: Collins, Sean E., et al.
Publicado: (2015)

Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals
por: Mesquita, Emersom C., et al.
Publicado: (2018)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

Dysregulation of iron metabolism modulators in virologically suppressed HIV-infected patients
por: Garrido-Rodríguez, Vanesa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_21tp0nocd6pil2gifi3qjp7lhb